BMRN vs. TMO: BioMarin Pharmaceutical vs. Thermo Fisher Scientific Stock Comparison

Company Profile

BioMarin Pharmaceutical (BMRN) and Thermo Fisher Scientific (TMO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BMRN is classified in Biotechnology while TMO is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

BioMarin Pharmaceutical (BMRN) reports a negative ROE of -0.31%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Thermo Fisher Scientific (TMO) reports 13.38%, ranking against industry peers normally.

BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile Thermo Fisher Scientific (TMO) reports 14.94%, ranking against industry peers normally.

Both BioMarin Pharmaceutical (BMRN) at 26.58% and Thermo Fisher Scientific (TMO) at 20.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both BioMarin Pharmaceutical (BMRN) at 12.87% and Thermo Fisher Scientific (TMO) at 3.91% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both BioMarin Pharmaceutical (BMRN) at -18.55% and Thermo Fisher Scientific (TMO) at 7.32% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Both BioMarin Pharmaceutical (BMRN) at 2.44 and Thermo Fisher Scientific (TMO) at 1.81 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both BioMarin Pharmaceutical (BMRN) at 0.67 and Thermo Fisher Scientific (TMO) at 0.75 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

BioMarin Pharmaceutical (BMRN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a yield of 0.27%, ranking against industry peers normally.

BioMarin Pharmaceutical (BMRN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a payout of 9.70%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Thermo Fisher Scientific (TMO) trades at 36.64 times trailing earnings, ranked against its peers, while BioMarin Pharmaceutical (BMRN) has no P/E ratio this period.

BioMarin Pharmaceutical (BMRN) at 2.97 sits in the cheaper P/S ratio quartile while Thermo Fisher Scientific (TMO) at 5.44 prices around its industry’s middle — BMRN costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both BioMarin Pharmaceutical (BMRN) at 1.73 and Thermo Fisher Scientific (TMO) at 4.70 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics